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Background: Candidate predictive biomarkers for epidermal growth factor receptor inhibitors (EGFRi), skin rash and
serum proteomic assays, require further qualification to improve EGFRi therapy in non-small cell lung cancer
(NSCLC). In a phase II trial that was closed to accrual because of changes in clinical practice we examined the
relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival.
Methods: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A)
cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. All received
cetuximab monotherapy for the first 14 days. Pre-treatment serum and weekly rash assessments by standard and
EGFRi-induced rash (EIR) scales were collected.
Results: 43 patients (20-Arm A, 23-Arm B) completed the 14-day run-in. Median survival was 9.1 months. Arm B
had better median overall (Arm B = 10.3 [95% CI 7.5, 16.8]; Arm A = 3.5 [2.8, 11.7] months P = 0.046) and
progression-free survival (Arm B = 2.3 [1.6, 3.1]; Arm A = 1.6 [0.9, 1.9] months P = 0.11). The EIR scale distributed
ratings among 6 rather than 3 categories but ordinal scale rash severity did not predict outcomes. The serum
proteomic classifier and absence of rash after 21 days of cetuximab did.
Conclusions: Absence of rash after 21 days of cetuximab therapy and the serum proteomic classifier, but not
ordinal rash severity, were associated with NSCLC outcomes. Although in a small study, these observations were
consistent with results from larger retrospective analyses.
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The monoclonal antibody inhibitor of epidermal growth
factor receptor (EGFR)- cetuximab adds modest benefit
to front-line chemotherapy in patients with previously
untreated advanced non-small cell lung cancer (NSCLC)
[1,2]. This benefit is cost-ineffective by reference stan-
dards [3,4]. The role of tumor EGFR expression in pre-
dicting benefit from adding cetuximab in NSCLC is
under investigation [5–7]. For the small molecule EGFR
inhibitor (EGFRi) erlotinib in NSCLC, skin rash and
serum proteomic assays were initially identified as candi-
date predictive biomarkers [8–10]. These findings sug-
gested that non-tumor biomarkers might predict subsets
of patients likely to benefit from administration of EGFRis,
including cetuximab. A retrospective landmark time-point
analysis in the BMS099 trial [2] and a pre-specified subset
analysis in the FLEX [7] trial demonstrated better out-
comes for patients who developed rash by the end of cycle
1 with cetuximab added to front-line therapy. These find-
ings suggested that rash is a candidate predictive clinical
biomarker for cetuximab in front-line NSCLC therapy but
to validate the marker would require another large, ran-
domized prospective study [11].
The scales for severity of rash from antineoplastic
drugs are crude instruments for determining therapeutic
decisions. The scales are structured to equate severity
across the full spectrum of adverse events and are de-
signed as tools for safe conduct of clinical trials. They
are not validated or intended as biomarkers for treat-
ment effects [12]. To ascertain cetuximab-induced rash,
Gatzemeier, et al. collapsed 20 different terms from the
MEDRA 10.0 adverse event database [7]. The prospective
use of clinician detection of rash as a biomarker might re-
quire more structured assessment. The pathophysiology
of the rash associated with EGFR inhibitors is most remin-
iscent of acne rosacea (rosacea)[12], for which a validated
severity scale has already been developed [13].
A serum mass spectrometry-based classifier assay seg-
regates candidates for EGFRi therapy into “good” and
“bad” prognosis groups [9]. In multiple studies of EGFRis,
the patients in the two groups had divergent survival pat-
terns, but not in NSCLC patients treated with cytotoxic
therapy, suggesting that the serum proteomic profile is a
predictive rather than prognostic marker. In studies of er-
lotinib in NSCLC: for first-line treatment [14] and when
combined with bevacizumab therapy [15] the assay again
predicted survival differences. The assay performed simi-
larly in multiple clinical studies of patients with squamous
cell carcinoma of the head and neck and in colorectal
cancer [16], including subsets of these patients treated
with cetuximab. Although commercially available as
VeriStrat® (Biodesix, Broomfield, USA), the assay has
not been prospectively qualified as a predictive marker
for EGFRi therapy.We conducted a randomized, phase II trial in previ-
ously treated NSCLC patients that compared the con-
current and sequential administration of cetuximab and
pemetrexed. A component of the trial was to conduct
preliminary development of biomarkers for cetuximab.
Specifically for this trial, we adapted the validated ros-
acea severity scale as an EGFRi-induced rash (EIR) scale
for better differentiation than the ordinal CTCAE scale
of rash assessments. Additionally, serial serum samples
were collected and stored at -80°C. The randomization
and 2-week run-in design of the trial enabled concurrent
analysis of rash rating and the serum assay as candidate
predictive markers for cetuximab therapy in NSCLC.
The trial closed prior to achieving its initially intended
accrual goals. The original hypothesis to be tested by the
trial was to determine in patients with NSCLC refractory
to previous chemotherapy whether concomitant treatment
with cetuximab and pemetrexed improved progression-
free survival compared with cetuximab monotherapy. We
estimated a sample of 40 patients per treatment group
based on many assumptions, including a relatively modest
difference in outcomes between the study arms. Our esti-
mates were inaccurate, and patients who were randomized
to the combination therapy arm had much better out-
comes than patients in the monotherapy arm. Addition-
ally, large clinical trials of pemetrexed revealed advantages
to early initiation of pemetrexed after first-line therapy,
and single-arm studies of cetuximab in unselected patients
revealed no benefit to cetuximab monotherapy in this
population. Therefore the study was closed after reaching
half of its intended accrual. The preponderance of avail-
able evidence now supports that the administration of
pemetrexed in the second-line treatment setting would be
superior to cetuximab monotherapy. We report the results
of this trial not to demonstrate a definitive assessment of
the difference in the randomized treatment arms, but
rather to provide the foundation for this biomarker devel-
opment exercise.
The trial was intended to study pharmacodynamic bio-
markers in unselected patients and collection of tumor
tissue was not incorporated into the study design. But
the study called for all patients to provide pre-treatment
serum samples and to undergo standardized, prospective
rash evaluations. There are many limitations to the suc-
cessful development of valid clinically relevant biomarkers
concurrently with novel anticancer agents. The need to
collect material for markers prospectively, combined with
the observation time required to accumulate outcome data
with which to qualify biomarkers makes the process slow
and expensive. In this manuscript we have examined the
data from this trial with 3 goals: 1) to explore the use of
quantitative changes in tumor burden at an early time-
point in a trial as a measure of drug effect (rather than
RECIST-based response or time to progression), 2) to
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data in this trial are consistent with retrospective analyses
of larger clinical trials, and 3) to perform a preliminary es-
timate of the value of intensive, quantitative rash assess-




The first patient enrolled in July 2005. The study closed to
accrual in March 2008 with minimum 6-month follow-up.
Eligible patients were ≥ 18 years with confirmed NSCLC
not amenable to curative therapy. All patients were previ-
ously treated with at least one platinum- or taxane-
containing chemotherapy regimen for locally advanced or
metastatic disease. Patients with: prior pemetrexed or
prior EGFRi therapy, more than two prior systemic anti-
cancer therapies, uncontrolled cardiac disease or pleural/
pericardial effusions, and those with the inability to inter-
rupt aspirin or other non-steroidal anti-inflammatory
agents for a 5-day period were excluded. Remaining eligi-
bility requirements were as previously described [17]. The
study was approved by the institutional review boards of
the University of Chicago and Ingalls Hospital and all par-
ticipants provided written informed consent.
Study design
Treatment
During a 2-week run-in, cetuximab was administered at
an initial dose of 400 mg/m2 over 120 minutes, followed
by weekly infusions at 250 mg/m2 over 60 minutes. Typical
dose adjustment and discontinuation criteria for cetuximab
were used [1,2]. Patients were randomized to treatment as-
signment at registration. On day 15, subjects assigned to
Arm B received 500 mg/m2 pemetrexed after cetuximab.
Pre-treatment folate and Vitamin B12 supplementation
were provided in accordance with the package insert. In
case of pemetrexed-related adverse events, doses were
initially adjusted to 375 mg/m2 and again to 250 mg/m2 if
required. Pemetrexed every 21 day cycles with weekly
cetuximab continued until progression. Patients random-
ized to Arm A remained on cetuximab monotherapy until
progression. Within 1–2 weeks of discontinuing cetuxi-
mab, these patients then crossed over to receive peme-
trexed and appropriate supportive therapy.
Assessments
Efficacy and safety evaluations
Tumor size was measured by computed tomography
(CT) at baseline, on days 34–40, days 55–61, and days
76–82. Thereafter, it was measured every 34–40 days
after previous CT scan while patients remained on study.
Tumor measurements, responses, and disease progres-
sion were assessed using RECIST [18]. The sum of thelongest dimensions of each target lesion was tracked
throughout the study and used to calculate the change
in tumor size as a quantitative assessment of treatment
effect [19,20]. Baseline brain MR imaging was not per-
formed. Patients who developed central nervous system
symptoms were referred for imaging. Survival was con-
firmed with treating physicians and the Social Security
Index when treating physicians were uncertain of date
of death.
Rash
Rash assessments were performed at baseline and weekly
through the 4th dose of cetuximab, no prophylactic
treatment was provided. Rashes were assessed by the
same clinician on both the CTCAE version 3 rash/des-
quamation scale and an EGFRi-Induced Rash Scale (EIR)
adapted from the validated rosacea severity scale [13]
(Table 1). CTCAE and EIR scales were compared by
plotting worst rash rating at any point in the first month
of treatment. Uniformly, the highest rating for each pa-
tient on each scale occurred at the same time. The max-
imum change in EIR rating from baseline to day 22 of
cetuximab therapy was used to evaluate the relationships
among serum proteomic predictor class, changes in
tumor size at the first CT imaging evaluation, and rash.
Serum collection and analysis
Serum samples were collected at baseline and at subse-
quent time-points but only the baseline samples were
analyzed. VeriStrat classifier was determined using coded,
de-identified samples without any information regarding
treatment assignment as previously described [15]. Codes
were returned to the principal investigator with assign-
ments of “good”, “bad”, or “undetermined.” Undetermined
samples were treated as missing data in all subsequent
analyses.
Statistical analysis
Progression-free survival (PFS) time was calculated from
the date of initial treatment on-study until determination
of disease progression radiographically or clinically, or
death regardless of attribution except for the analysis
looking at the relationship with rash where PFS was cal-
culated from day 22 of study therapy and two patients
with progression or death prior to day 22 were excluded.
Patients last known to be alive and progression-free
were censored at the date of last CT scan without evi-
dence of progression. Based on data available prior to
the initiation of the trial, we expected a sample of 40 pa-
tients per treatment arm would achieve 80% power at a
0.1 significance level to detect an improvement in the
progression-free survival rate at twelve weeks from 50%
to 66%.
Table 1 Rash rating scales used in this investigation
Grade EGFR-Inhibitor induced rash scale CTCAE Assessment scale
0 No rash No rash
1 Isolated pustule or erythematous patch < 1 cm in diameter, on
either face/head/neck or chest/back
Macular or papular eruption or erythema without associated symptoms
2 More than one erythematous patch or erythema and
telangiectasia on either face/head/neck or chest/back
Macular or papular eruption or erythema with pruritus or other
associated symptoms; localized desquamation or other lesions covering
< 50% of body surface area
3 More than one pustule or papules on either face/head/neck
or chest/back with no associated erythema or telangiectasia
Severe, generalized erythroderma or macular, papular or vesicular eruption;
desquamation covering ≥ 50% body surface area
4 Both erythema/telangiectasia and pustules/papules limited to
either face/head/neck or chest/back
Generalized exfoliative, ulcerative, or bullous dermatitis
5 Pustules or papules and erythema/telangiectasia present on
both the face/head/neck region and the chest/back
Death
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groups were estimated using the Kaplan-Meier procedure
and compared with the log-rank test. In the comparison
of overall survival between treatment arms, there was evi-
dence of non-proportional hazards, and therefore the
Wilcoxon-Gehan test [21] (which assigns greater weight
to earlier time-points) rather than the log-rank test is
presented. Results from Wilcoxon-Gehan tests are also re-
ported for the landmark analyses.
Candidate biomarker evaluation
Given the rapidly changing definitions of standard ther-
apies in NSCLC during the course of the study, it be-
came clear in late 2007 that the enrollment goal would
not be achieved, and so the focus of the investigation
was reoriented to evaluation of candidate biomarkers in
relation to the quantitative assessment of treatment ef-
fects with change in tumor size over the first 8 weeks of
therapy. For the serum proteomic classifier, 10/43 (23%)
evaluable patients did not have a pre-treatment serum
marker classification. Fisher’s exact test was used for com-
parisons of treatment assignment, histology, and sex be-
tween those with serum marker data and those without.
During the course of the trial, independent groups
conducted modeling studies to determine whether the
change in the sum of the longest dimensions of target le-
sions for NSCLC at 8 weeks of therapy would be an ac-
ceptable primary endpoint for phase II clinical trials
[19,20,22]. The primary motivations for use of Response
Evaluation Criteria in Solid Tumors (RECIST) in phase II
clinical trials and the shortcomings of response rate and
progression-free survival as endpoints in small randomized
trials have been well addressed elsewhere [19,23–28]. To
maximize our sensitivity for detecting differences in per-
formance of biomarkers for cetuximab, we applied the
novel quantitative variable derived from the modeling
studies, the log ratio of tumor size at 8 weeks of treat-
ment versus baseline, as an experimental measure of
treatment effect in the context of these data. The log ofthe ratio of the tumor size at the first evaluation on
treatment (t1) to the baseline tumor size (t0) was used
and defined as follows: log(t1/t0) = log(t1) – log(t0). As
previously proposed, non-measurable negative outcomes
are assigned poor outcome quantitative values and ana-
lyzed using rank-based procedures [19]. Specifically, the
one early death prior to the first CT scan on treatment
was assumed to have the worst possible outcome, and
the four subjects with brain MRIs confirming new me-
tastases at the first evaluation were assumed to be tied
with the worst progressor. The nonparametric Wilcoxon
rank-sum test was used for comparison of change in
tumor size between treatment and serum marker groups.
A Spearman rank correlation coefficient was calculated
to assess the association between change in tumor size
and change in rash.
Results
Patient characteristics
Fifty-five patients were enrolled over a three-year period
from July 2005 to March 2008. Of these patients, 43 re-
ceived at least three doses of cetuximab, and were
deemed evaluable. The patients are described in Table 2.
The drop-out rate was not unusual for a second-line
therapy trial in the pre-pemetrexed era, especially be-
cause this trial pre-specified that only patients who com-
pleted the 3-dose, 2-week run-in of cetuximab would be
considered evaluable. Five patients were withdrawn be-
cause of infusion reaction to cetuximab, 3 patients with-
drew because of inconvenience of commuting to the
clinic site, 1 patient could not get pain adequately con-
trolled and withdrew to begin immediate cytotoxic ther-
apy, 1 patient had symptomatic progression of bony
metastasis at day 15, 1 patient died suddenly and unex-
pectedly at week 4, and 1 patient withdrew prior to the
first imaging evaluation for intolerability of grade 2 rash.
Of the 43 evaluable patients, 33 had pre-treatment sam-
ples on which the serum proteomic assessment could be
completed. There was no statistically significant difference
Table 2 Baseline and disease characteristics for
randomized, evaluable patients
Characteristic Arm A (cetuximab
alone)
Arm B (cetuximab +
pemetrexed)





Men 14 (70) 13 (57)
Women 6 (30) 10 (43)
Ethnicity: No. (%)
White 13 (65) 17 (74)
African-American 7 (35) 5 (22)
Asian 0 (0) 1 (4)
Smoking history: No. (%)
Current 7 (35) 6 (26)
Past 11 (55) 13 (57)
Never 2 (10) 2 (9)
Unknown 0 (0) 2 (9)
Histology: No. (%)
Unspecified 7 (35) 9 (39)
Squamous 6 (30) 8 (35)
Adenocarcinoma 7 (35) 6 (26)
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0.14), treatment assignment (P = 0.29), or histology (P =
0.70). There were 21 patients determined to have a “good”
serum predictor status and 12 a “bad” status.
Clinical outcomes
For the 43 evaluable patients, median PFS was 1.6 months
[95% CI 1.6, 2.4] and median overall survival (OS) was
9.1 months [95% CI 5.6, 11.7]. Median PFS for Arm A was
1.6 [95% CI 0.9, 1.9] months, less than the 2.3 months
[95% CI 1.6, 3.1] for Arm B (P = 0.11) (Figure 1a). Arm B
appeared to have superior overall survival (10.3 [95% CI
7.5, 16.8] vs. 3.5 [95% CI 2.8, 11.7] months (P = 0.046))
(Figure 1c). Analysis of the effect of the serum prote-
omic assay classifier suggested superior PFS (P = 0.029)
(Figure 1b) and overall survival (P = 0.038) (Figure 1d)
for the individuals with the “good” classification. Only
25% of those with the “bad” classification were random-
ized to Arm B while 62% of those with the “good” classifi-
cation were assigned to Arm B and so in this small study,
the treatment arm assignment might confound the assess-
ment of the serum proteomic classifier and vice-versa.
Rash scales
At each of the pre-specified time-points (pre-treatment,
after two doses of cetuximab, after third dose ofcetuximab, prior to fourth dose of cetuximab, and every
three weeks thereafter) patients were assessed by the
same clinician for rash using the two scales; the novel
EIR and the CTCAE (Table 1). A comparison of the
worst rash rating for each patient by each scale (Figure 2)
shows the EIR scale to distribute the typical range of
rash more broadly than CTCAE. The CTCAE grade 1
subjects are mostly distributed among 1, 2, and 3 on the
EIR scale, while CTCAE grade 2 subjects are distributed
primarily among 3, 4, and 5 on the EIR scale.
A landmark analysis was performed to examine the as-
sociation among PFS, OS and rash development by C1D8
(after 21 days of cetuximab therapy as in Gatzemeier,
et al.) with the EIR and CTCAE scales. Using the thresh-
old of rash of grade 1 or higher at any time, ignoring
presence of baseline rash, gave the same results on both
scales. Rash did not predict improved PFS (P = 0.91),
but trended toward an association with improved OS
(P = 0.06).
Change in tumor size and biomarker evaluations
Evaluable patients had CT scans conducted pre-treatment
and between days 18 to 60; most patients had the initial
post-treatment scan performed between days 34–40. We
compared the change in tumor size between each patient’s
first two scans (Figure 3a) by treatment groups. There was
a significant difference in the initial change in tumor
size with greater increase in Arm A compared to Arm B
(P = 0.032), consistent with the findings on PFS between
the two groups.
We then tested the associations among this change in
tumor size with the serum proteomic classifier and rash.
“Good” serum predictor status was associated with more
favorable changes in tumor size (P = 0.014) (Figure 3b).
It was then investigated if a patient’s maximum change
in EIR rating from baseline to day 22 of study treatment
had any correlation with change in tumor size (Figure 4).
The Spearman rank correlation coefficient was 0.15
(p = 0.35, N = 41), indicating no association between rash
severity and change in tumor size in this cohort. Given
the small sample and the absence of any association be-
tween rash and treatment outcome, a test for interaction
between rash rating and serum proteomic predictor was
not performed. But no individual in the “bad” predictor
cohort showed any benefit of cetuximab monotherapy,
even those who developed grade 2 through grade 5 rash.
The potential value of further distributing rash ratings
across a broader ordinal scale is likely to be low.
Discussion
This exploratory randomized phase II trial with a 2-
week run-in of cetuximab monotherapy could inform
future development of predictive biomarkers for EGFRi
therapy in NSCLC. The biomarker development concepts










Figure 2 Comparison of worst rash scores per patient by EIR
and CTCAE scales.
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validated rosacea scale for EIR-rating, 2) use of modified
quantitative assessment of tumor size changes to assess
marker relationships, and 3) concomitant assessment of can-
didate markers, rash and serum proteomic profiling in the
same patients. The EIR scale distributed rash ratings across
a larger ordinal range than the conventional CTCAE rash
scale; however this scaling did not strengthen the association
with treatment outcomes beyond that of the categorical
“rash vs. no rash” approach employed by Gatzemeier, et al.
[7]. The serum proteomic predictor was associated with
treatment outcomes in this study of cetuximab and peme-
trexed in the second-line treatment of NSCLC, although this
finding might be due to confounding with treatment arm.
As a small trial, not meeting its intended accrual goals,
there are clear limitations to this study. The setting of
advanced NSCLC meant many patients deteriorated
during or immediately after investigational treatment. As
the value of information was not clear at the time of con-




























Figure 3 Change in tumor size by arm (a) and serum proteomic classifier (b). The log of the ratio of the tumor size at the first evaluation
on treatment (T1) to the baseline tumor size (T0) is plotted for each subject. The top red dashed line marks RECIST criteria for progressive disease
at the time of the first CT scan, any values at or below the bottom dashed red line meet RECIST criteria for response, and those meeting criteria
for stable disease lie in between the two dashed lines. Circles represent actual measured values, while triangle symbols indicate those subjects
with brain MRIs confirming new metastases at the first evaluation and therefore equated with the change in tumor size of the worst progressor.
The early death in Arm B was assigned a T1/T0 value of 2.5 (log(T1/T0) = 0.92).
Figure 4 Change in tumor size vs. change in EIR rash score.
This is a plot of each individual, evaluable patient from this trial. The
x-axis represents the change in EIR from baseline to C1D8. The y-axis
represents the change in tumor size by log ratio of tumor burden at
week 8 to baseline. Each patient is further represented by which
arm to which they were randomized (red for Arm A, blue for Arm B)
and serum predictor (x for poor, circle for good). The plot reveals
potentially informative trends: 1) the top 5 tumor responses (the
most negative log ratios) were among subjects randomized to Arm
B, all of whom had “good” predictor status, but had rash changes on
the EIR of 0, 1, 2, 4, and 5; 2) Of the early progressors (11 subjects
with log ratio > 0.18 at or before the first imaging session), 8 had
some evidence of rash and 5 had among the most severe rashes
with an EIR rating change of 4 or 5; 3) No patient with a “poor”
serum proteome predictor had any tumor shrinkage at all, but only
2 of these subjects were randomized to receive pemetrexed at the
end of the 2-week run-in.
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randomization by tumor histology. We had competing tri-
als at that time that required information on tissue type
for enrollment and a PS of only 0 or 1. This study unin-
tentionally enrolled a typically more ill population with
few never smokers (10%), fewer than usual women (under
40%), and many patients with non-adenocarcinoma or un-
known histology (70%). The actual sample size meant only
large effects, such as the benefit of immediate initiation of
pemetrexed, could be detected with conventional mea-
sures such as progression-free and overall survival. The
randomization did not effectively free the assessment from
bias. This is highlighted by the unusually poor median-
survival time in Arm A, 3.5 months is even low for a best-
supportive care only trial. Arm A had fewer women, had
patients with a higher median age, and more patients with
serum proteome-profile-predicted “poor” outcomes with
cetuximab monotherapy. It is therefore unclear the extent
to which the treatment assignment versus the small sam-
ple size have biased the outcomes of this trial by study
arm. The results are consistent with prior evidence of the
value of timely treatment with pemetrexed in second-line
treatment of NSCLC [29,30]. Despite not reaching original
accrual goals for the study, Arm B subjects, treated con-
currently with pemetrexed and cetuximab, had better pro-
gression free and overall survival than Arm A subjects
treated with sequential cetuximab followed by peme-
trexed, reaching statistical significance for the latter. Not-
ably, of the 20 evaluable patients who were randomized to
Arm A, 10 did not maintain sufficiently good performance
status to receive the pemetrexed after progression.
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CTCAE, but there is no evidence that this broader dis-
tribution will improve upon use of rash severity as a pre-
dictive marker for cetuximab efficacy in NSCLC. Serial
skin biopsies were performed on a subset of patients in
this study, but the heterogeneity of the specimens in
terms of estimated volume, estimated total number of
cells, enumerated EGFR-expressing cells and ratio of
EGFR-expressing to total cells, as well as relative mRNA
expression of candidate normalization molecules (data
not shown) made semi-quantitative and correlative ana-
lyses impossible. Dose-to-rash studies with EGFRi have
not revealed a significant benefit for increasing the se-
verity of rash [31,32]. Our data are consistent with the
observations of others in larger trials, that incidence and
not relative severity of EIR appears to be the pharmaco-
dynamically relevant biomarker [7,10].
Cetuximab monotherapy has no evident value in the
treatment in unselected NSCLC patients in the second-
line setting. Some could argue that cetuximab therefore
has limited if any role in combination therapy. However,
the data from Gatzemeier, et al. [7], suggest that a
biomarker-based selection of patients who should re-
ceive cetuximab added to standard chemotherapy could
yield improved outcomes over those reported for the
cetuximab arm in the FLEX trial. This circumstance is
increasingly common in oncology therapeutics, an agent
that has limited but evident benefit in combination can-
not be used ethically as monotherapy. Therefore, the
early development monotherapy trials become an im-
portant opportunity with which to characterize candi-
date biomarkers and conduct preliminary validation and
comparative estimate studies. In this “pure” setting, in-
vestigators can determine the typical time course, inten-
sity, and interindividual variance in candidate markers.
In a single disease, investigators can conduct prelimin-
ary comparisons to make estimates regarding which
markers represent the best opportunities for future val-
idation and qualification studies in large trials, including
combination therapy trials.
For future qualification of candidate markers of EGFRi
in the treatment of NSCLC, we propose that either the
serum proteomic assay or incidence of rash be further
evaluated as a means to exclude patients from receipt of
cetuximab therapy. In patients who have the “poor”
proteomic profile and those who fail to develop rash by
21 days of cetuximab therapy the likelihood of benefit-
ting from cetuximab therapy appears low. In NSCLC,
these markers, similar to the use of KRAS mutations in
colorectal cancer, have reproducibly associated with ab-
sence of benefit from EGFRi therapy [14–16,33]. Our
findings suggest future strategies to qualify these bio-
markers for clinical use would be to demonstrate pro-
spectively in a randomized trial that either or bothmarkers effectively reduces the unnecessary, toxic, inef-
fective, and expensive use of cetuximab [11]. Ideally, this
study should help to identify safe and more effective al-
ternatives for the patients who will not benefit from
cetuximab therapy.
Conclusions
Typical phase II trials of combination therapy have had
limited impact on the overall development of cancer
therapeutics [34]. Here we have demonstrated a strategy
of: a brief monotherapy run-in, randomization, concurrent
assessment of candidate biomarkers, and implementation
of quantitative tumor size assessments as a potential means
to make a local phase II trial more informative. The results
of this study suggest that future development of either EIR
or a serum proteomic predictor assay might focus on
qualifying these markers to exclude prior to or early in
treatment patients who have a low likelihood of benefiting
from these expensive, potentially toxic therapies.
Competing interests
CHC participated in an ad hoc advisory board meeting for and received
compensation from Biodesix during the conduct of this investigation.
Authors’ contributions
MLM conceived of the initial protocol design with EEV and together drafted
the protocol. In the first year of the study EEV served as principal investigator
and MLM served the remaining years, coordinated efforts of the co-authors
on sample and statistical analyses and interpretation and with MRL organized
data, drafted all figures, and the first draft of the manuscript. MEL conceived
and developed the EIR rating scale, contributed to the design and conduct
of the trial and performed serial skin biopsies on initial patients enrolled in
the study and KS assumed those responsibilities for the remainder of the
study. KEW performed statistical analyses and drafted part of the manuscript.
CHC supervised all analyses with the serum proteomic predictor, interpreted
study results and modified the manuscript. IOG supervised analyses of skin
biopsies and participated in interpretation of rash rating results. LS and GR
provided patient care and ensured adherence to the study protocol. MFK,
PCH, and RS enrolled patients, provided patient care, performed rash ratings
and disease response assessments. DPC contributed to study design, provided
funding and technical support on serum proteomic predictor analyses. TGK
developed the initial study design and supervised KEW in all study-related
analyses and interpretations. All authors read, commented upon and approved
the final manuscript.
Acknowledgements
The authors wish to thank Drs. WanQing Liu and Aliya Husain for important
intellectual contributions and Lijun He and Qudsia Arif for expert technical
assistance.
Funding
This work was supported by Bristol-Myers Squibb through a contract for
completion of the clinical and translational investigation to the University of
Chicago. Additional support was provided by the University of Chicago
Comprehensive Cancer Center. Biodesix provided blinded serum proteomic
assay determinations. Dr. Maitland initiated this trial while enrolled in the
Clinical Therapeutics Training Program (NIH/NIGMS T32 GM 007019).
Author details
1University of Chicago, Section of Hematology/Oncology, 5841 S Maryland
Ave, MC 2115, Chicago, IL 60637, USA. 2University of Chicago, Section of
Dermatology, 5841 S Maryland Ave, MC 5067, Chicago, IL 60637, USA.
3University of Chicago, Committee on Clinical Pharmacology and
Pharmacogenomics, 900 E 57th St, KCBD 6121, Box 11, Chicago, IL 60637,
USA. 4University of Chicago, Comprehensive Cancer Center, 5847 S Maryland
Maitland et al. BMC Cancer 2014, 14:5 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/5Ave, MC 1140, Chicago, IL 60637, USA. 5Department of Health Studies,
University of Chicago, 5841 S Maryland Ave, MC 2007, Chicago, IL 60637,
USA. 6Department of Pathology, University of Chicago, 5841 S Maryland Ave,
MC 6101, Chicago, IL, USA. 7Memorial Sloan-Kettering Cancer Center, 1275
York Ave, New York, NY 10065, USA. 8Johns Hopkins University, Kimmel
Cancer Center, Suite 1100, 401 N Broadway, Baltimore, MD 21287, USA.
9Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN
37232, USA. 10Ingalls Hospital, One Ingalls Dr, Harvey, IL 60426, USA.
Received: 29 April 2013 Accepted: 12 December 2013
Published: 4 January 2014
References
1. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R,
Vynnychenko I, Park K, Yu CT, Ganul V, et al: Cetuximab plus
chemotherapy in patients with advanced non-small-cell lung cancer
(FLEX): an open-label randomised phase III trial. Lancet 2009,
373(9674):1525–1531.
2. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC,
Paschold E, Iannotti NO, Dakhil S, Gorton S, et al: Cetuximab and first-line
taxane/carboplatin chemotherapy in advanced non-small-cell lung
cancer: results of the randomized multicenter phase III trial BMS099.
J Clin Oncol 2010, 28(6):911–917.
3. Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer,
and the $440 billion question. J Natl Cancer Inst 2009, 101(15):1044–1048.
4. Joerger M, Matter-Walstra K, Fruh M, Kuhnel U, Szucs T, Pestalozzi B,
Schwenkglenks M: Addition of cetuximab to first-line chemotherapy in
patients with advanced non-small-cell lung cancer: a cost-utility analysis.
Ann Oncol 2011, 22(3):567–574.
5. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S,
Hermann RC, Lynch TJ, Weber MR: Analysis of potential predictive
markers of cetuximab benefit in BMS099, a phase III study of cetuximab
and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
J Clin Oncol 2010, 28(6):918–927.
6. O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM,
Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, et al: Molecular biomarkers in
non-small-cell lung cancer: a retrospective analysis of data from the
phase 3 FLEX study. Lancet Oncol 2011, 12(8):795–805.
7. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE,
Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, et al: First-cycle rash
and survival in patients with advanced non-small-cell lung cancer receiving
cetuximab in combination with first-line chemotherapy: a subgroup analysis
of data from the FLEX phase 3 study. Lancet Oncol 2011, 12(1):30–37.
8. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp
D, Rigas J, Clark GM, Santabarbara P, Bonomi P: Determinants of tumor
response and survival with erlotinib in patients with non–small-cell lung
cancer. J Clin Oncol 2004, 22(16):3238–3247.
9. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M,
Brahmer J, Spreafico A, Ludovini V, et al: Mass spectrometry to classify
non-small-cell lung cancer patients for clinical outcome after treatment
with epidermal growth factor receptor tyrosine kinase inhibitors:
a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99(11):838–846.
10. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation
between development of rash and efficacy in patients treated with the
epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in
two large phase III studies. Clin Cancer Res 2007, 13(13):3913–3921.
11. Perrone F: Cetuximab in NSCLC: another trial needed. Lancet Oncol 2011,
12(1):3–4.
12. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB,
Barasch A, Einhorn L, Wagner L, et al: A proposed EGFR inhibitor
dermatologic adverse event-specific grading scale from the MASCC skin
toxicity study group. Support Care Cancer 2010, 18(4):509–522.
13. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F:
Standard grading system for rosacea: report of the National Rosacea
Society Expert Committee on the classification and staging of rosacea.
J Am Acad Dermatol 2004, 50(6):907–912.
14. Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone
DP: Genetic and proteomic features associated with survival after
treatment with erlotinib in first-line therapy of non-small cell lung cancer
in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010,
5(2):169–178.15. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J,
Tsypin M, Herbst RS, Tsao AS, et al: VeriStrat classifier for survival and time
to progression in non-small cell lung cancer (NSCLC) patients treated
with erlotinib and bevacizumab. Lung Cancer 2010, 69(3):337–340.
16. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA,
Argiris A, Forastiere AA, Gilbert J, et al: Detection of tumor epidermal
growth factor receptor pathway dependence by serum mass
spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 2010,
19(2):358–365.
17. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher
AW, Villalona-Calero M, Sandler A, Chaudhuri T, et al: Phase I and
pharmacokinetic study of pemetrexed administered every 3 weeks to
advanced cancer patients with normal and impaired renal function.
J Clin Oncol 2006, 24(4):552–562.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, et al: New
guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst 2000, 92(3):205–216.
19. Karrison TG, Maitland ML, Stadler WM, Ratain MJ: Design of phase II cancer
trials using a continuous endpoint of change in tumor size: application
to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl
Cancer Inst 2007, 99(19):1455–1461.
20. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J:
Elucidation of relationship between tumor size and survival in non-small-cell
lung cancer patients can aid early decision making in clinical drug development.
Clin Pharmacol Ther 2009, 86(2):167–174.
21. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily
singly-censored samples. Biometrika 1965, 52:203–223.
22. Claret L, Andre V, De Alwis D, Bruno R: Modeling and simulation to assess
the use of change in tumor size as primary endpoint in Phase II studies
in oncology. In Population Approach Group Europe. Marseille, France; 2008.
Abstract 1386.
23. Fojo AT, Noonan A: RECIST: no longer the sharpest tool in the oncology
clinical trials toolbox–reply to point. Cancer Res 2012, 72(20):5150.
24. Fojo AT, Noonan A: Why RECIST works and why it should stay–
counterpoint. Cancer Res 2012, 72(20):5151–5157. discussion 5158.
25. Maitland ML, Bies RR, Barrett JS: A time to keep and a time to cast away
categories of tumor response. J Clin Oncol 2011, 29(23):3109–3111.
26. Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ: Early average
change in tumor size in a phase 2 trial: efficient endpoint or false
promise? J Natl Cancer Inst 2007, 99(19):1422–1423.
27. Sharma MR, Maitland ML, Ratain MJ: Why RECIST works and why it should
stay–reply to counterpoint. Cancer Res 2012, 72(20):5158.
28. Sharma MR, Maitland ML, Ratain MJ: RECIST: no longer the sharpest tool in
the oncology clinical trials toolbox–-point. Cancer Res 2012,
72(20):5145–5149. discussion 5150.
29. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL,
Bover I, Begbie S, Tzekova V, et al: Maintenance pemetrexed plus best
supportive care versus placebo plus best supportive care for non-small-
cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009,
374(9699):1432–1440.
30. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O,
Sahoo TP, Laack E, Reck M, et al: Maintenance therapy with pemetrexed
plus best supportive care versus placebo plus best supportive care
after induction therapy with pemetrexed plus cisplatin for advanced
non-squamous non-small-cell lung cancer (PARAMOUNT): a double-
blind, phase 3, randomised controlled trial. Lancet Oncol 2012,
13(3):247–255.
31. Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM,
Ricart A, Chu QS, Tolcher AW, Wood L, et al: Erlotinib 'dosing-to-rash':
a phase II intrapatient dose escalation and pharmacologic study of
erlotinib in previously treated advanced non-small cell lung cancer.
Br J Cancer 2011, 105(7):938–944.
32. Tejpar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F,
Glimelius B, Ciardiello F, Kisker O, Van Cutsem E: Phase I/II study of
cetuximab dose-escalation in patients with metastatic colorectal cancer
(mCRC) with no or slight skin reactions on cetuximab standard dose
treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and
efficacy data. ASCO Meet Abstr 2007, 25(18_suppl):4037.
Maitland et al. BMC Cancer 2014, 14:5 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/533. Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA: Validation of
treatment induced specific adverse effect as a predictor of treatment
benefit: a case study of NCIC CTG BR21. Contemp clin trials 2008,
29(4):527–536.
34. Maitland ML, Hudoba C, Snider KL, Ratain MJ: Analysis of the yield of
phase II combination therapy trials in medical oncology. Clin Cancer Res
2010, 16(21):5296–5302.
doi:10.1186/1471-2407-14-5
Cite this article as: Maitland et al.: Evaluation of a novel rash scale and a
serum proteomic predictor in a randomized phase II trial of sequential
or concurrent cetuximab and pemetrexed in previously treated
non-small cell lung cancer. BMC Cancer 2014 14:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
